Global Anti-influenza Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Anti-influenza Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Anti-influenza Drugs are drugs used to treat people with influenza. Influenza is an acute respiratory infectious disease caused by influenza virus, which is short for influenza. Symptoms usually include fever, head and body aches, cough, and a stuffy or runny nose. At present, the common anti-influenza drugs mainly include oseltamivir, zanamivir and peramivir.

Market Overview:

The latest research study on the global Anti-influenza Drugs market finds that the global Anti-influenza Drugs market reached a value of USD 1271.66 million in 2023. It’s expected that the market will achieve USD 2245.83 million by 2029, exhibiting a CAGR of 9.94% during the forecast period.

High prevalence and impact of influenza

Influenza, commonly known as the flu, is an infectious disease caused by influenza viruses. Most influenza patients will develop self-limiting upper respiratory tract symptoms. Some influenza patients (especially young children, the elderly, pregnant women, or patients with certain underlying diseases) may develop influenza-related complications, and in severe cases, death. There are 4 types of influenza viruses: A, B, C and D. Influenza A and B viruses spread and cause seasonal disease epidemics. According to the World Health Organization (WHO), there are approximately 1 billion seasonal influenza cases every year, including 3 million to 5 million severe cases. Seasonal influenza causes 290,000 to 650,000 respiratory deaths each year. According to the U.S. Department of Health and Human Services, influenza causes 9.4 million to 41 million illnesses, 100,000 to 710,000 hospitalizations, and 4,900 to 52,000 deaths in the United States each year between 2010 and 2022. The seasonal nature of influenza and the potential for severe outbreaks, such as the 2009 H1N1 influenza pandemic, highlight the need for effective drugs to prevent and treat the virus. Therefore, the high prevalence and impact of influenza are the major drivers of market growth.

Region Overview:

In 2022, the share of the Anti-influenza Drugs market in China stood at 69.11%.

Company Overview:

HEC Pharm is one of the major players operating in the Anti-influenza Drugs market, holding a share of 36.87% in 2023.

HEC Pharm is a biopharmaceutical company. It is engaged in the research of biologic drugs, drug development, production and sale of APIs, and production and sale of pharmaceutical products. The company is focused on such therapeutic areas as infections, cardiovascular diseases, oncology, and metabolism.

Segmentation Overview:

By type, Oseltamivir segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Adults segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Anti-influenza Drugs market covered in Chapter 3:

Amneal Pharmaceuticals, Inc.
Cipla
GlaxoSmithKline
BioCryst Pharmaceuticals Inc.
HEC Pharm
Roche
Hunan Nucien Pharmaceutical

In Chapter 4 and Chapter 14.2, on the basis of types, the Anti-influenza Drugs market from 2019 to 2030 is primarily split into:

Oseltamivir
Zanamivir
Peramivir
Other

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Anti-influenza Drugs market from 2019 to 2030 covers:

Children
Adults
Elderly

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)